United States · Biotechnology startup
United States · 4D Molecular Therapeutics
4D Molecular Therapeutics designs, develops, and commercializes transformative gene therapeutic products for unmet medical conditions.
Funding reportedLast round: Post ipo equity
What company datasets say 4D Molecular Therapeutics raised
Funding, as reported
Reported in all$595Min dollars
Rounds6
Last roundPost ipo equity
Last round dateFeb 2024
Investors listed19
SEC Form D$109M sold, 3 filings, last Sept 2018
Founders and team
From 4D Molecular Therapeutics's own website and the SEC filings it signed: 1 founder, 9 on the team.
Theresa JankeChief of Staff, Co-FounderNamed on its 2018 Form D
- Chris SimmsChief Commercial & Business Officer
- Kim MaplestoneChief Clinical Operations Officer
- Kristian HumerChief Financial Officer
- Glenn P. SblendorioBoard Member
- Nancy Miller-RichBoard Member
- David KirnExecutive Officer, Directori
- David SchafferExecutive Officer, Directori
- Leisa JohnsonExecutive Officeri
- Peter FrancisExecutive Officeri
On the board, as filediCharles TheuerHoyoung HuhMargi McLaughlinTony Yao
On 3 portfolio pages
Investors who name them
Each firm lists 4D Molecular Therapeutics on its own website. That is the firm's claim, a weaker thing than a round we watched, but a named source.
Biotechnology in United States
Startups like it
- SojournixWaltham · founded 2016Raised
- Receptor Life SciencesSeattle · founded 2017Raised
- Attune PharmaceuticalsNew York · founded 2018Raised
AbbVieNorth Chicago · founded 2012
GrailMenlo Park · founded 2015
EQRxCambridge · founded 2019- Cerevel TherapeuticsBoston · founded 2018
Royalty PharmaNew York · founded 1996
Is this your company?
Add your raise, your deck and your story, and put 4D Molecular Therapeutics in front of investors. Or tell us what we have wrong.